Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation

NCT00895297 is registered in ClinicalTrials.gov with European Society for Blood and Marrow Transplantation as lead sponsor.

NCT NCT00895297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00895297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation
Lead sponsor
European Society for Blood and Marrow Transplantation
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2010
Completion date
November 30, 2011
Enrollment
50 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia